Combined company expected to trade on Nasdaq under “KLRS” after closing PALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) — Kalaris Therapeutics, Inc. (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent diseases of the retina, and AlloVir, Inc. (Nasdaq: ALVR) announced today the results for the proposals voted upon by AlloVir stockholders at a Special Meeting of Stockholders held on March 12, 2025. The AlloVir stockholders voted in favor of all proposals at the Special Meeting, including to approve the proposed merger between the companies. The closing of the merger is expected to occur as soon as practicable, subject to the satisfaction or waiver of the remaining customary closing conditions. Following the closing of the merger,...

The 284-unit property preserves affordable housing in the Portland, OR MSA VANCOUVER, Wash., March 12, 2025 (GLOBE NEWSWIRE) — Preservation Equity Fund Advisors, LLC (PEF Advisors), a real estate private equity group focused on preserving existing affordable housing in high-cost markets, announced their recent acquisition of Prairie View Apartments, a 284-unit apartment community in Vancouver, WA, a suburb located 25 minutes north of Portland, OR. Originally built in 1990 and redeveloped with low-income housing tax credits in 2008, the property restricts residents to 60% of Area Median Income. The property includes 30 residential buildings. The buildings are spread across 18.42 acres, providing a low-density layout with 14 units per acre. The property features 66 one-bedroom units, 152 two-bedroom units and 66 three-bedroom units,...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree THRUVISION GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW Wendel announces the successful placement of Bureau Veritas shares as part of a prepaid 3-year forward sale representing approximately 6.7% of Bureau Veritas share capital and increases its financial flexibility by reducing the pro forma1 loan-to-value ratio to approximately 17% Wendel today announces the successful placement of 30,357,140 shares of Bureau Veritas (representing approximately 6.7% of Bureau Veritas’ share capital2) at a price of €27.25 per share (the “Offering Price”). As indicated in the press release published yesterday, Wendel entered into a prepaid 3-year forward sale agreement with BNP Paribas...

SUFFOLK, Va. and MIDLOTHIAN, Va., March 11, 2025 (GLOBE NEWSWIRE) — Hampton Roads based TowneBank (NASDAQ: TOWN) and Village Bank and Trust Financial Corp. (NASDAQCM: VBFC) (“Village”) today announced that the Federal Deposit Insurance Corporation and the Virginia State Corporation Commission have approved the regulatory applications filed in connection with TowneBank’s acquisition of Village and its wholly-owned subsidiary, Village Bank. In addition to the parties receiving all required regulatory approvals, the merger received the approval of Village’s shareholders, with more than 86% of the outstanding shares voting for the merger at Village’s special meeting of shareholders held on December 19, 2024. The merger is expected to be completed at the beginning of April 2025, subject to the satisfaction of customary closing conditions...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW Wendel announces the entry into a prepaid 3-year forward sale of Bureau Veritas shares representing 6.7% of share capital, together with an option to retain partial share price upside, and increases its financial flexibility by reducing the pro forma1 loan-to-value ratio to c.17% Wendel to retain 26.5% of the share capital and 41.2% of voting rights of Bureau Veritas Wendel today announces that it has entered into a prepaid 3-year forward sale agreement with BNP Paribas (the “Forward Bank“) (subject to the effective completion of the Offering as described below) for 30,357,140 shares2 (representing...

$10.9 Million Development to Preserve 80 Affordable UnitsThe office building located at the GardenWalk of PocArk – Arkoma propertyWNC & Associates (WNC) and Belmont Development Company (BDC) have closed a deal to acquire three affordable housing properties, GardenWalk of Pocola, GardenWalk of PocArk – Pocola and GardenWalk of PocArk – Arkoma, in Arkoma and Pocola, Oklahoma.ARKOMA, Okla. and POCOLA, Okla., March 11, 2025 (GLOBE NEWSWIRE) — WNC & Associates (WNC), a family-owned business known as both a pioneer and leader in the affordable housing industry, and Belmont Development Company (BDC), an Oklahoma-based developer with expertise in affordable housing through USDA-Rural Development and Low-Income Housing Tax Credits (LIHTC), have closed a deal to acquire three affordable housing properties,...

TORONTO, March 11, 2025 (GLOBE NEWSWIRE) — Quisitive Technology Solutions, Inc. (“Quisitive” or the “Company”) (TSXV: QUIS; OTCQX: QUISF), a premier Microsoft Cloud and AI solutions provider, is pleased to announce the successful completion of the previously announced plan of arrangement under the Business Corporations Act (British Columbia) (the “Transaction”) pursuant to which, among other things, an affiliate of funds managed by of H.I.G. Capital (the “Purchaser”) acquired all of the issued and outstanding common shares of Quisitive (the “Shares”) for C$0.57 per Share in cash, other than Shares previously held by certain employees who entered into rollover agreements. The Company received the final order from the Supreme Court of British Columbia approving the Transaction on March 4, 2025, and the Shares are expected to be delisted...

TAMPA, Fla., March 11, 2025 (GLOBE NEWSWIRE) — Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, today announced that it has signed a binding Letter of Intent (LOI) to acquire 100% of Choice Specialty Pharmacy Group (“Seller”), a fully licensed and prominent provider of specialized pharmacy services in the U.S., through an option purchase agreement. This acquisition is expected to further strengthen Better Choice’s specialty pharmacy presence in the U.S. and the purchase price is based on 6X of Seller’s FY2024 Adjusted EBITDA1 of approximately USD $4.68 million1, and consideration will be comprised of stock and cash at closing. “With the addition of Choice Specialty Pharmacy Group alongside our SRx platform in Canada, we are now executing on our...

BOSTON, March 11, 2025 (GLOBE NEWSWIRE) — Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics, today announced that patient dosing has been completed in its MUSIC-HFrEF Phase 1/2a clinical trial of the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction (HErEF). HErEF is a prevalent form of heart disease that accounts for half of an estimated 64.3 million heart failure cases worldwide and is currently considered a mass market incurable disease. The MUSIC-HFrEF trial is an open-label, uncontrolled study investigating SRD-001 across two cohorts with six patients dosed with SRD-001 in Cohort A (low-dose 3×1013 vg per patient) and three patients dosed...